Asset Details
Do you wish to reserve the book?
Assessment of liver fibrosis using a 3-dimensional high-resolution late gadolinium enhancement sequence in children and adolescents with Fontan circulation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Assessment of liver fibrosis using a 3-dimensional high-resolution late gadolinium enhancement sequence in children and adolescents with Fontan circulation
Do you wish to request the book?
Assessment of liver fibrosis using a 3-dimensional high-resolution late gadolinium enhancement sequence in children and adolescents with Fontan circulation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Assessment of liver fibrosis using a 3-dimensional high-resolution late gadolinium enhancement sequence in children and adolescents with Fontan circulation
2023
Overview
Objectives
To assess abnormal liver enhancement on 15–20 min delayed 3D high-resolution late gadolinium enhancement (3D HR LGE) sequence in patients with Fontan circulation.
Methods
Retrospective study of pediatric Fontan patients (< 18 years old) with combined cardiac-liver MRI from January 2018 to August 2021. Abnormal hepatic enhancement was graded (0–3) for each lobe, summed for a total liver enhancement score (0–6), and compared to repaired tetralogy of Fallot (rTOF) patients. Correlations with other hepatic imaging biomarkers were performed. Temporal relationships of enhancement compared to traditional early portal venous and 5–7-min delayed phase liver imaging were analyzed.
Results
The Fontan group (
n
= 35, 13 ± 3.4 years old, median time from Fontan 10 (9–12) years) had 23/35 (66%) with delayed 3D HR LGE total liver enhancement score > 0 (range 0–5), with greater involvement of the right lobe (1 (0–1) vs 0 (0–1),
p
< 0.01). The rTOF group (
n
= 35, 14 ± 2.6 years old) had no abnormal enhancement. In the Fontan group, total liver enhancement was 3 (2–4) in the early portal venous phase, lower at 1 (1–2) in the 5–7-min delayed phase (
p
< 0.01), and lowest at 1 (0–2) in the 15–20-min delayed phase (
p
= 0.03). 3D HR LGE enhancement correlated inversely with portal vein flow (
r
s
= − 0.42,
p
= 0.01) and positively with left lobe stiffness (
r
s
= 0.51,
p
< 0.01). The enhancement score decreased in 13/35 (37%) between the 5–7- and 15–20-min delayed phases.
Conclusions
Liver fibrosis can be assessed on 3D HR LGE sequences in patients with Fontan circulation, correlates with other imaging biomarkers of Fontan liver disease, and may add information for hepatic surveillance in this population.
Key Points
• Abnormal liver enhancement on 3D HR LGE sequences in Fontan patients likely represents liver fibrosis and is seen in up to 66% of children and adolescents with variable distribution and severity.
• The degree of 3D HR LGE liver enhancement correlates with decreased portal vein flow and increased left hepatic lobe stiffness.
